UTI Biomarker Detection Device for Polymicrobial Infection Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for urinary tract infections (UTIs), such as standard urine culture (SUC), are limited in detecting non-E. coli pathogens and polymicrobial infections, leading to false negatives and inadequate treatment, especially in geriatric and pediatric populations with atypical symptoms.
Innovation Solution
A point-of-care device that detects UTI-associated biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), interleukin-8 (IL-8), and interleukin-1-beta (IL-1β) in urine samples, using a system with detection zones and sensors to indicate UTI presence with higher sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard urine culture (SUC) is used to diagnose UTIs, then the diagnostic method is simple and widely available, but it fails to detect non-E. coli pathogens and polymicrobial infections, leading to false negatives
Solution Approach 1:
The patent segments the UTI diagnostic process into multiple independent detection channels, each targeting specific biomarkers (NGAL, IL-8, IL-1β). This segmentation allows the system to detect different types of urinary tract infections simultaneously, improving both reliability and adaptability without requiring a single complex test to cover all pathogens.
Solution Approach 2:
The diagnostic system is designed with multi-functionality to detect multiple biomarkers (NGAL, IL-8, IL-1β) that indicate different types of urinary tract infections. This universal approach allows a single test system to identify E. coli infections, non-E. coli infections, and polymicrobial infections, thereby expanding the pathogen detection range while maintaining diagnostic simplicity.
2Ease of operation
If standard urine culture (SUC) is used for UTI diagnosis, then the test is easy to perform, but it produces false negatives in geriatric and pediatric populations with atypical symptoms
Solution Approach 1:
The patent changes the detection parameters from culturing live bacteria (SUC) to measuring biomarker concentrations (NGAL, IL-8, IL-1β) in urine. This parameter change enables detection of urinary tract infections in geriatric and pediatric populations with atypical symptoms, improving measurement precision while maintaining ease of operation through simple urine sample collection and automated biomarker analysis.
3Measurement precision
If more sensitive culture techniques or gene sequencing are used to detect uropathogens, then the detection sensitivity increases, but it becomes difficult to determine whether detected microbes are associated with actual UTI and inflammation
Solution Approach 1:
The patent uses inflammation biomarkers (NGAL, IL-8, IL-1β) as intermediaries to connect pathogen detection with clinical UTI diagnosis. These biomarkers serve as mediators that indicate active inflammation and immune response, allowing the system to distinguish between asymptomatic bacteriuria and true UTIs with high precision, thereby recovering the inflammation association information that was lost in direct culture methods.
Data Source
AI summary
Current UTI diagnostics face sensitivity challenges, especially with fastidious organisms and polymicrobial infections. Diagnosing UTIs in geriatric and pediatric patients, including those with communication difficulties like dementia, adds complexity due to atypical symptoms. Thus, systems, devices, and methods for UTI diagnosis across diverse patient groups are described herein. These methods utilize urinary biomarkers (NGAL, IL-8, IL-1β) to differentiate UTIs from asymptomatic bacteriuria. A consensus criterion, requiring≥2 biomarkers, achieves high sensitivity (84.0%), specificity (91.2%), and accuracy (86.9%). This biomarker consensus enhances UTI diagnosis in compact diagnostic systems, especially when standard urine culture and multiplex PCR results diverge.